ELI LILLY AND CO. news, videos and press releases - Page 7
For more news please use our advanced search feature.
ELI LILLY AND CO. - More news...
ELI LILLY AND CO. - More news...
- Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
- Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
- Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System
- Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
- CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
- Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement
- Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
- Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
- Lilly Appoints Philip Johnson to Senior Vice President and Treasurer
- New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis
- ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
- Consolidated Research: 2018 Summary Expectations for Union Pacific, HCA Holdings, PulteGroup, Amgen, Eli Lilly, and AES Corp – Fundamental Analysis, Key Performance Indications
- ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
-
Eli Lilly To Cut 8 Percent Of Jobs
- Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eli Lilly and Company (LLY)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY
- U.S. FDA Issues Complete Response Letter for Baricitinib
- Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement
- Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences
- Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students
- Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017
- Lilly and the William Sansum Diabetes Center announce a five-year research collaboration
- Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
- First dedicated outcome trials of empagliflozin in chronic heart failure initiated
- IBRI, Lilly, Dow AgroSciences Partner to Develop Shared Database to Assess Molecular Safety
-
Eli Lilly CEO on GOP health care plan: Seems like a reasonable, concrete plan
- New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis
- Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®'
- Lilly Announces Changes in Senior Management
